The vaccine was administered in 3 doses spaced 2 weeks apart. Efficacy On 22 June 2021, The official Cuban government sources reported that the results of an initial study by the Cuban Center for Genetic Engineering and Biotechnology involving 48,290 participants found a 92.28% efficacy rate at preventing symptomatic COVID-19. The report included a confidence interval of without a specified confidence level; analysis was based on 153 cases of symptomatic COVID, 142 of which were in the placebo group and 11 of which were in the approximately equal vaccinated group. The measure of efficacy includes the initial strain of SARS-COV-2 as well as variants that were present in Cuba during the study, including Alpha, Beta, and Gamma strains. The Beta variant entered Cuba in January 2021 and became the predominant strain in Cuba, fuelling a rise in COVID cases. As of 28 June 2021, Cuba has not yet released detailed information about the vaccine to the WHO or to the general public via a pre-print or a scientific article. It is planned to do so after the Cuba Health Agency (CECMED) authorises the vaccine for emergency use.
Abdala 
Tabun 
Kuru 
Kuru
Samu
Kava
WebTeb
Koro 